Reduction or prevention of kidney disease progression · people with sickle cell disease
1 finding from 1 review
Serious adverse events · people with sickle cell disease
Hydroxyurea showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Quality of life · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reduction or prevention of kidney disease progression · people with sickle cell disease
1 finding from 1 review
Serious adverse events · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (12 months) · weight reduction in obesity to improve survival in women with endometrial cancer
1 finding from 1 review
Overall survival (24 months) · weight reduction in obesity to improve survival in women with endometrial cancer
It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes overall survival (24 months) compared with usual care compared to placebo (very low certainty).
1 finding from 1 review
Adverse events – musculoskeletal · weight reduction in obesity to improve survival in women with endometrial cancer
It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes adverse events – musculoskeletal compared with usual care compared to placebo (very low certainty).
1 finding from 1 review
Cancer‐specific survival (24 months) (Number of cancer‐related deaths) · weight reduction in obesity to improve survival in women with endometrial cancer
1 finding from 1 review
Weight loss (change in kg weight) · weight reduction in obesity to improve survival in women with endometrial cancer
1 finding from 1 review
Cardiovascular and metabolic event frequency (12 months) (Number of strokes, myocardial infarctions and hospitalisations for heart failure) · weight reduction in obesity to improve survival in women with endometrial cancer
Summary of findings table ‐ Lifestyle intervention showed no clear difference in cardiovascular and metabolic event frequency (6 months) compared with usual care compared to placebo (low certainty).
1 finding from 1 review
Quality of life: FACT‐G (12 months) · weight reduction in obesity to improve survival in women with endometrial cancer
1 finding from 1 review
Relapse: return to any drinking at end of treatment · alcohol use disorder
Summary of findings table ‐ Baclofen probably leads to lower relapse: return to any drinking at end of treatment compared with placebo (moderate certainty).
1 finding from 1 review
Frequency of use % days abstinence at the end of treatment · alcohol use disorder
1 finding from 1 review
Frequency of use % of heavy drinking days at the end of treatment · alcohol use disorder
1 finding from 1 review
Amount of use drink per drinking days at the end of treatment · alcohol use disorder
1 finding from 1 review
Adverse events: number of participants with ≥ 1 adverse event at end of treatment · alcohol use disorder
Summary of findings table ‐ Baclofen showed no clear difference in adverse events: number of participants with ≥ 1 adverse event at end… compared with placebo (high certainty).
1 finding from 1 review
Dropout · alcohol use disorder
Summary of findings table ‐ Baclofen showed no clear difference in dropouts at end of treatment compared with placebo (high certainty).
1 finding from 1 review